2. Signaling Pathways
  3. Others
  4. Isotope-Labeled Compounds

Isotope-Labeled Compounds

Isotope-labeled compounds are chemical substances in which some atoms in their molecules are replaced by isotope atoms. The range of stable isotope products can cover from gases to complex molecules. Isotope-labeled compounds could provide a site-specific investigation of structures, making molecules easily detectable by mass spectrometry and NMR, and maintaining the physico-chemical properties of the target molecule at the same time. MCE isotope-labeled compounds are all stable isotope-labeled compounds and are non-radioactive labeled substances. MCE isotope-labeled compounds are unique tools for identifying and understanding biological and chemical processes. Stable isotope-labeled products are now getting more and more popular among scientists. The scope of application is gradually penetrating into various scientific fields, such as life sciences, food and medicine, agriculture, environment, geology, etc. Stable isotope-labeled compounds have a wide range of applications in the Life Science areas, such as Metabolomics, Proteomics, Clinical studies, Deuterium drugs, etc.

Isotope-Labeled Compounds Related Products (7658):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-Y1119S
    1-Bromonaphthalene-d7
    		98.91%
    1-Bromonaphthalene-d7 is the deuterium labeled 1-Bromonaphthalene[1].
    1-Bromonaphthalene-d<sub>7</sub>
  • HY-17376S
    Ezetimibe-d4
    		98.84%
    Ezetimibe-d4 is the deuterium labeled Ezetimibe. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
    Ezetimibe-d<sub>4</sub>
  • HY-135170S
    Myristoyl-L-carnitine-d3 chloride
    		99.94%
    Myristoyl-L-carnitine-d3 (chloride) is the deuterium labeled Myristoyl-L-carnitine chloride[1].
    Myristoyl-L-carnitine-d<sub>3</sub> chloride
  • HY-B0144BS
    Pitavastatin-d4 sodium
    		99.67%
    Pitavastatin-d4 (sodium) is deuterium labeled Pitavastatin (sodium).
    Pitavastatin-d<sub>4</sub> sodium
  • HY-113359AS2
    Uridine 5'-diphosphate-13C9,15N2 dilithium
    		99.5%
    Uridine 5'-diphosphate-13C9,15N2 dilithium is 13C and 15N-labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a P2Y6 receptor agonist with an EC50 of 0.013 μM for human P2Y6 receptor.
    Uridine 5'-diphosphate-<sup>13</sup>C<sub>9</sub>,<sup>15</sup>N<sub>2</sub> dilithium
  • HY-32181S
    Fluorenone-d8
    9H-fluoren-9-one-d8 is the deuterium labeled 9H-fluoren-9-one[1].
    Fluorenone-d<sub>8</sub>
  • HY-W110999S
    9-Nitroanthracene-d9
    		99.93%
    9-Nitroanthracene-d9 is the deuterium labeled 9-Nitroanthracene[1].
    9-Nitroanthracene-d<sub>9</sub>
  • HY-N0729S4
    Linoleic acid-d5
    		≥98.0%
    Linoleic Acid-d5 is the deuterium labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism.
    Linoleic acid-d<sub>5</sub>
  • HY-10569S1
    Ponesimod-d7
    Ponesimod-d7 (ACT-128800-d7) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d7 (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod-d7 activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod-d7 can protect against lymphocyte-mediated tissue inflammation.
    Ponesimod-d<sub>7</sub>
  • HY-B0631S
    Alendronic acid-d6
    		≥98.0%
    Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].
    Alendronic acid-d<sub>6</sub>
  • HY-B0656AS
    Rabeprazole-d4 sodium
    		98.61%
    Rabeprazole-d4 (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
    Rabeprazole-d<sub>4</sub> sodium
  • HY-13757AS
    Tamoxifen-d5
    		99.99%
    Tamoxifen-d5 is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity.
    Tamoxifen-d<sub>5</sub>
  • HY-50904S1
    Nintedanib-13C,d3
    		≥99.0%
    Nintedanib-13C,d3 is the 13C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib-<sup>13</sup>C,d<sub>3</sub>
  • HY-10162S1
    Olaparib-d8
    		99.57%
    Olaparib-d8 (AZD2281-d8) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator.
    Olaparib-d<sub>8</sub>
  • HY-B0507S
    Sulfathiazole-d4
    		99.90%
    Sulfathiazole-d4 is a deuterium labeled Sulfathiazole. Sulfathiazole is an orally active, endocrine disruptor targeting the steroidogenic pathway, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRN expression of CYP17, CYP19, and 3β-HSD. Sulfathiazole increases the production of 17-estradiol (E2) and has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish.
    Sulfathiazole-d<sub>4</sub>
  • HY-B0389S8
    D-Glucose-d1-4
    		≥98.0%
    D-Glucose-d-44 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
    D-Glucose-d<sub>1</sub>-4
  • HY-143915S
    Amitriptyline-N-glucuronide-d3
    Amitriptyline-N-glucuronide-d3 is the deuterium labeled Amitriptyline-N-glucuronide[1].
    Amitriptyline-N-glucuronide-d<sub>3</sub>
  • HY-N0092S
    Inosine-2,8-d2
    		99.69%
    Inosine-2,8-d2 is the deuterium labeled Inosine. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors.
    Inosine-2,8-d<sub>2</sub>
  • HY-N0682S3
    Pyridoxine-13C4 hydrochloride
    		98.00%
    Pyridoxine-13C4 (hydrochloride) is the 13C-labeled Pyridoxine (hydrochloride). Pyridoxine hydrochloride (Pyridoxol; Vitamin B6) is a pyridine derivative. Pyridoxine (Pyridoxol; Vitamin B6) exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway.
    Pyridoxine-<sup>13</sup>C<sub>4</sub> hydrochloride
  • HY-N1131S
    Triacetonamine-d17
    		99.72%
    Triacetonamine-d17 (2,2,6,6-Tetramethyl-4-piperidone-d17) is the deuterium labeled Triacetonamine. Triacetonamine has oral activity and can induce acute liver failure (ALF) in rats.
    Triacetonamine-d<sub>17</sub>